Early Rhythm Control Therapy Remains Effective for Atrial Fibrillation Patients with Obesity and Diabetes
核心洞察
Secondary analysis of the EAST-AFNET 4 trial demonstrates that early rhythm control therapy maintains its efficacy and safety in atrial fibrillation (搜索) patients with obesity (搜索) or diabetes (搜索).
The study found no significant differences in cardiovascular outcomes between patients with and without obesity (搜索) or diabetes (搜索) when receiving early rhythm control therapy.
Results challenge historical reluctance to offer rhythm control therapy to patients with obesity (搜索), suggesting neither obesity nor diabetes (搜索) should preclude early treatment.
A secondary analysis of the landmark EAST-AFNET 4 trial has revealed that early rhythm control (ERC) therapy maintains its effectiveness and safety profile in atrial fibrillation (搜索) (AF) patients with obesity (搜索) or diabetes (搜索), challenging traditional treatment approaches for these high-risk populations.
The findings, published in JAMA Cardiology, demonstrate that neither obesity (搜索) nor diabetes (搜索) significantly impacts the therapeutic benefit of early rhythm control therapy, which reduced cardiovascular complications by approximately 20% compared to usual care over a median follow-up of 5.1 years.
Study Design and Patient Population
The original EAST-AFNET 4 trial enrolled 2,789 patients with AF diagnosed at least one year before enrollment and at least two CHA2DS2-VASc risk factors. Patients were randomly assigned to receive either ERC therapy—consisting of anti-arrhythmic drug therapy (搜索), catheter ablation, or cardioversion—or usual care.
For this secondary analysis, researchers led by Paulus Kirchhof from University Medical Center Hamburg-Eppendorf (搜索) examined outcomes in 1,086 patients with obesity (搜索) (BMI ≥30 kg/m²) compared to 1,690 patients without obesity, and 694 patients with diabetes (搜索) versus 2,090 without diabetes.
Comparable Efficacy Across Patient Groups
The analysis revealed that ERC therapy remained equally effective regardless of obesity (搜索) status. Among patients with obesity (mean BMI 34.5 kg/m²), 522 received ERC therapy, primarily anti-arrhythmic drug therapy (搜索). The hazard ratios for the composite primary outcome were comparable between groups: 0.84 for patients with obesity and 0.69 for those without obesity.
Similarly, diabetes (搜索) status did not significantly alter the treatment effect, with hazard ratios of 0.77 for patients with diabetes and 0.78 for those without diabetes. The primary outcome encompassed death from cardiovascular causes, stroke (搜索), or hospitalization with worsening heart failure (搜索) or acute coronary syndrome (搜索).
Safety Profile Remains Consistent
Safety outcomes showed no significant differences between patient groups. For patients with and without obesity (搜索), composite safety outcome rates were 13.4% and 18.5%, respectively. Stroke (搜索) rates were 1.1% versus 3.9%, death rates were 7.9% versus 11.2%, and serious adverse events occurred in 5.4% versus 4.5% of patients.
Among patients with diabetes (搜索), the primary safety outcome occurred in 18.2% compared to 16.1% in those without diabetes, with no statistically significant difference observed.
Clinical Implications for Practice
The researchers emphasize that these findings have important implications for clinical care, particularly given the historical reluctance of cardiologists to offer rhythm control therapy to patients with obesity (搜索). Traditional recommendations often suggested achieving weight loss prior to initiating rhythm control therapy.
"The analysis of safety outcomes suggests that established anti-arrhythmic drugs can be safely used in patients with obesity (搜索)," the investigators noted. They recommend that "early initiation of rhythm control therapy should be part of the initial management in patients with obesity with recently diagnosed AF."
Patient Characteristics and Comorbidities
Patients with obesity (搜索) in the study were younger than those without obesity (mean age 68 vs 72 years) and had higher rates of nonparoxysmal AF patterns (31% vs 24%), arterial hypertension (搜索) (94.8% vs 83.3%), and stable heart failure (搜索) (32.7% vs 12.0%). However, they had lower rates of stroke (搜索) or transient ischemic attack (9.2% vs 13.2%).
Patients with diabetes (搜索) were also younger (mean age 69 vs 71 years), more often male (61.0% vs 51.1%), had higher mean BMI (31.3 vs 28.6 kg/m²), and were more likely to have arterial hypertension (搜索) (92.8% vs 86.3%) and stage 3 or 4 chronic kidney disease (搜索) (16.1% vs 11.4%).
Future Treatment Considerations
The researchers acknowledge that the EAST-AFNET 4 trial was conducted before glucagon-like peptide-1 receptor agonists (搜索) became widely available. However, they argue that the "lack of interaction of ERC across the ranges of BMI suggests that ERC will retain its efficacy in patients with obesity (搜索) and diabetes (搜索) receiving such interventions."
The study authors conclude definitively: "Put simply, neither obesity (搜索) nor diabetes (搜索) should be a reason to withhold ERC therapy in patients with AF," providing clear guidance for clinicians treating this complex patient population.